Clinical Observation Of Yiqi Wenyang Bushen Rrescription In The Treatment Of Patients With Low Risk Or Intermediate Risk-1 Myelodysplastic Syndrome

Objective:To observe the clinical efficacy and safety of YiqiWenyangBushen Rrescription in the treatment of patients with Myelodysplastic Syndrome((low risk or intermediate risk-1))(Myelodysplastic syndrome,MDS),and to provide effective Chinese medicine treatment for patients with MDS(low risk or intermediate risk-1)Methods:A total of 49 patients with myelodysplastic syndrome who were hospitalized or outpatient in the Hematology Department of Hubei Provincial Hospital of Traditional Chinese Medicine from October 2017 to October 2019 were collected for clinical research.According to the International Integral Prognosis System(IPSS)grouping,they are classified as MDS/Medium Danger-1).Randomly divide the patients into 24 cases in the control group and 25 cases in the treatment group.There was no statistically significant difference between the two groups in terms of gender,age,distribution of outpatient or inpatients,diagnosis classification,IPSS score and risk,and first-complicated comorbidities(P >0.05).No cases of shedding occurred.Patients in the control group were given testosterone undecanoate and conventional supportive treatment with western medicine.The treatment group was given Yifangyangyangshen formula on the basis of western medicine treatment in the control group.The course of treatment was 3 months.The clinical symptoms,peripheral blood,bone marrow,blood transfusion,and adverse reactions of the two groups of patients were observed before and after treatment,and statistical analysis was performed using SPSS23.0 software.P <0.05 was considered statistically significant.Results: 1.After 3 months of treatment,the clinical efficacy of the treatment group was 6 cases of basic remission,12 cases of partial remission,4 cases improved,3 cases were ineffective,and the total effective rate was 88.0%;the clinical efficacy of the control group was 1 case of basic remission,8 cases were partially relieved,5 cases were hematologically improved,10 cases were ineffective,and the total effective rate was 58.3%.The difference in total clinical efficacy between the two groups was significant(P <0.05).2.After treatment,the blood routine comparison between the two groups showed that the hemoglobin in both groups was significantly higher than the pre-treatment level(P<0.05),and the hemoglobin and white blood cells in the treatment group were significantly higher than those in the control group(P <0.05).3.The degree of myeloproliferation was not significantly different between the two groups before and after treatment(P > 0.05).The erythropathic hematopoiesis of the treatment group was significantly better than before treatment(P <0.05),and there was no significant difference in megakaryocytic and granulocyte morbid hematopoiesis between and within the group(P >0.05).4.After treatment,the blood transfusion volume of the treatment group was significantly reduced,and the effective rate of blood transfusion reduction was significantly better than that of the control group(P <0.05).5.After 3 months of treatment,the TCM symptom score of the treatment group was significantly lower than that of the control group(P <0.05).In the treatment group,1 case was cured,8 cases were markedly effective,12 cases were effective,and the total effective rate was 84%;in the control group,0 cases were cured,5 markedly effective,7 cases were effective,and the total effective rate was 50%.Better than the control group(P <0.05).6.Safety evaluation: There was no obvious liver and kidney function damage in the treatment group,and one patient had oral ulcers.After symptomatic treatment,the symptoms disappeared.Two patients in the control group developed mild liver dysfunction,which was considered to be related to the side effects of Antell,and the transaminase returned to normal after liver treatment.There was no significant difference in renal function,urine routine,fecal routine and electrocardiogram before and after treatment between the two groups.Conclusion: YiqiWenyangBushen Rrescription has significant clinical efficacy in treating patients with myelodysplastic syndrome(low risk/intermediate risk-1),which can effectively improve the hemoglobin level of patients;to a certain extent,improve peripheral blood and bone marrow images of patients,reduce blood transfusion volume,and improve clinical Symptoms and good safety.